Table 1. Effects of GS-0976 on plasma glucose, triglyceride, total cholesterol, and insulin concentrations.

Mice		Control	MC4R KO
Treatment		Vehicle	Vehicle	GS-0976
Dose (mg/kg/day)				4	16
		(n = 5)	(n = 8)	(n = 8)	(n = 8)
Total cholesterol (mg/dL)	Pre	91 ± 4	363 ± 35	373 ± 42	371 ± 48
	Post	85 ± 6**	389 ± 39	264 ± 37##	249 ± 28##
Triglyceride (mg/dL)	Pre	111 ± 10	96 ± 23	94 ± 19	106 ± 29
	Post	86 ± 26	90 ± 35	170 ± 47##	152 ± 54##
Glucose (mg/dL)	Pre	146 ± 7	140 ± 6	133 ± 10	133 ± 13
	Post	149 ± 9	143 ± 16	163 ± 15#	173 ± 18##
Insulin (ng/mL)	Pre	0.9 ± 0.4	12.4 ± 5.8	13.7 ± 7.7	16.2 ± 6.3
	Post	0.7 ± 0.1**	9.4 ± 3.9	59.9 ±39.8##	79.3 ±22.7##

Plasma parameters were measured in lean control mice (Control, n = 5) and MC4R KO mice (n = 8) before (Pre) and after 8-week treatment (Post). Data are represented as the mean ± SD,

**p<0.01 vs. MC4R KO mice treated with vehicle by Aspin-Welch test.

^#p<0.025,

^##p<0.005 vs. MC4R KO mice treated with vehicle by one-tailed Williams’ test or one-tailed Shirley-Williams test.